Navigation Links
AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Date:5/13/2008

QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the article titled "Placebo-controlled dose-ranging Phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia (BPH", has been accepted for publication in an upcoming issue of the European Urology Journal. Written by F.M.J. Debruyne, Department of Urology, Academic Hospital Nijmegen, The Netherlands, A.A. Gres, Clinical Urology MOKB, Minsk, Belarus, and D.L. Arustamov, Center of Urology, Ministry of Health of Republic of Uzbekistan, the article refers to results of a Phase 2 trial with cetrorelix in BPH, which showed a prolonged improvement in BPH symptoms and uroflow, persisting up to the end of the 20-week observation period.

These results are part of previously disclosed Phase 2 data on cetrorelix in BPH through prior abstracts and poster presentations. The article is available online at http://www.europeanurology.com

Prof. Jurgen Engel, Ph.D., Executive Vice President, Scientific Affairs at AEterna Zentaris commented, "We are very proud to have the work of Prof. Debruyne and his colleagues on cetrorelix published in this prestigious peer reviewed European journal. The article, along with the recent Best Poster Presentation Award that Prof. Debruyne received last March at the 23rd Annual European Association of Urology Meeting, is another acknowledgement of the quality of our development program with cetrorelix in BPH."

THE ABSTRACT

Background and Objectives

Pilot studies with da
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, ... Family purchased a DNA test to unravel ... with a lifetime of memories, sharing, and closeness. In ... DNA genuinely brought the family closer together. , ... genetic history and prior to taking the genetic ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Nanometre-scale gold particles are currently intensively investigated for ... carriers and molecular electronics. The particles are prepared ... reactive gold cores can be stabilised with various ... by using organothiolate ligands that have a strong ...
... Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... testing, hematopoietic stem cell processing, and stem cell storage services, ... first nine months of fiscal year 2011 ended December 31, ... of Fiscal 2011 Highlights Revenue ...
... 2011 Epeius Biotechnologies ( www.epeiusbiotech.com ) announced today that ... Company,s lead anti-cancer agent, Rexin-G , the first, and ... to seek out and destroy metastatic cancer. According to Dr. ... in terms of clinical development, is that the Rexin-G product, ...
Cached Biology Technology:Fingerprints of a gold cluster revealed 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 2
(Date:7/11/2014)... Chicago is creating a new professorship in tissue ... Institute for Molecular Engineering and the Marine Biological ... the Millicent and Eugene Bell Foundation., The Eugene ... the Institute for Molecular Engineering. That endowed chair ... the MBL,s Eugene Bell Center for Regenerative Biology ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... This release is available in German . ... hibernating common pipistrelle bats under harsh conditions of snow cover. ... Max Planck Institute for Ornithology in Seewiesen and their colleagues ... birds alternative feed, they ate it and showed little or ...
... parasites from spreading throughout the body has seen Dr ... named a Young Tall Poppy by the Australian Institute ... postdoctoral fellow in the institute,s Infection and Immunity division, ... parasite,s movement. "Malaria parasites use a unique ...
... Park of Cornell University, who receives funding for basic ... (AFOSR), is investigating carbon nanostructures that may some day ... for the Air Force. "Devices that are required ... different from commercial ones in the sense that they ...
Cached Biology News:Great tits eat bats in times of need 2Malaria research wins Jake Baum a Young Tall Poppy award 2AFOSR's basic research may lead to revolutionary new devices 2
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... demand is causing shortages in your laboratory ... can cause unwanted distractions, problems and delays. ... for your hard work and endeavour! Bring ... it up,and market it internationally. We work ...
... shortages in your laboratory or fellow researchers want ... problems and delays. • ... Bring us your idea and let us build ... under ISO 9001 quality assurance in design, development, ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: